In contrast, the currently recommended molecular-targeted therapies for gastric cancer are trastuzumab, which targets erb-b2 receptor tyrosine kinase 2 (ERRB2) (also known as HER2), and ramucirumab, which targets kinase insert domain receptor (KDR) (also known as VEGFR2) [3]. This evidence concerns the gene ERBB2 and gastric cancer.